Screening of DPD Deficiency before Fluoropyrimidine Chemotherapy
Dr Felix Wong
Consultant Chemical Pathologist, Queen Mary Hospital
Volume 19, Issue 1, Jan 2024 (download full article in pdf)
Screening of dihydropyrimidine dehydrogenase (DPD) deficiency before systemic fluoropyrimidine chemotherapy can improve safety and prevent the occurrence of the associated toxicity. Both genotyping and phenotyping approaches have been advocated. In this review, Dr Felix Wong compares and contrasts both approaches and explains the upcoming situation in Hong Kong in the near future. We welcome any feedback or suggestions. Please direct them to Dr Esther Hung of Education Committee, the Hong Kong College of Pathologists. Opinions expressed are those of the authors or named individuals, and are not necessarily those of the Hong Kong College of Pathologists.